Repare Therapeutics INC Form 4 insider transactions

Repare Therapeutics CEO, Lloyd Mitchell Segal, sold common shares between March 25-27, 2024, to cover tax obligations related to vested restricted stock units.

EVP and CFO of Repare Therapeutics, Steve Forte, reports the acquisition of stock options and restricted stock units (RSUs) in the company.

EVP and Chief Scientific Officer of Repare Therapeutics, Michael Zinda, reports acquisition of restricted stock units and stock options, along with disposition of common shares.

CEO Lloyd Mitchell Segal reports acquisition of restricted stock units and stock options, along with indirect holdings through Arvala Inc.

EVP and Chief Medical Officer of Repare Therapeutics Inc., Maria Koehler, reports acquisition of restricted stock units and stock options.